Skip to main content

Table 4 Mean changes in HRQoL scores from baseline to study phase completion (week 16) by categories of change in pain ratings, all dose groups combined

From: Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

  Categories of change in pain ratings
  > +10 (n = 31) +10 to -10 (n = 66) -11 to -20 (n = 37) -21 to -40 (n = 28) < -40 (n = 20) F p-value
PRO Instruments        
SF-36        
Physical functioning -2.0 (19.6) 1.7 (13.7) 8.9 (19.7) 13.2 (14.4) 20.3 (22.9) 6.1 0.0001
Role physical -1.5 (19.7) 4.5 (18.1) 11.0 (20.1) 19.2 (20.6) 26.3 (30.1) 8.0 0.0000
Bodily pain -7.3 (13.9) 4.0 (13.4) 15.1 (15.0) 20.5 (16.3) 33.9 (22.3) 28.4 0.0000
General health -4.4 (11.0) 0.6 (13.8) 3.6 (12.8) 7.1 (14.6) 17.8 (13.1) 9.8 0.0000
Vitality 0.4 (13.9) -0.3 (15.6) 7.6 (19.4) 12.7 (16.4) 28.8 (27.5) 11.8 0.0000
Social functioning -6.0 (24.8) -0.6 (18.9) 9.8 (17.9) 10.7 (28.6) 24.4 (39.4) 6.4 0.0001
Role emotional -7.8 (18.7) 1.4 (23.6) 5.4 (21.4) 10.0 (29.8) 24.6 (32.2) 5.9 0.0002
Mental health -2.7 (14.6) 2.4 (15.4) 3.5 (17.4) 8.6 (17.2) 15.5 (27.1) 3.9 0.0047
Physical summary -0.3 (6.3) 1.1 (4.8) 4.6 (5.7) 6.6 (5.0) 9.9 (1.8) 15.1 0.0000
Mental summary -2.7 (8.3) 0.3 (8.4) 2.0 (8.3) 3.9 (10.9) 10.4 (17.1) 5.9 0.0002
HAQ-DI 0.08 (0.36) -0.06 (0.33) -0.26 (0.36) -0.46 (0.39) -0.86 (0.51) 21.9 0.0000
FACIT-Fatigue 0.2 (5.7) 0.6 (7.4) 4.2 (5.0) 8.8 (8.2) 10.7 (9.1) 14.0 0.0000